Dextran Administration and Acute Kidney Injury in Pediatric Dengue Shock Syndrome: A Multicenter Propensity Score-Matched Cohort Study

Background: Acute kidney injury (AKI) complicates up to 10% of dengue virus infections, with the risk increasing with disease severity. Dextran-40, recommended as first-line colloid therapy for dengue shock syndrome (DSS) in Thailand's national guidelines, has theoretical nephrotoxic potential; however, evidence regarding its association with AKI in children with DSS remains limited.

Methods: This multicenter observational cohort study included children under 15 years diagnosed with DSS and admitted to six hospitals in Thailand between January 2012 and December 2024. Patients with refractory shock requiring inotropes within the first hour, bleeding complications, or AKI prior to fluid resuscitation were excluded. AKI was defined according to the KDIGO criteria. Propensity score matching was performed to balance baseline covariates between dextran-40 recipients and comparators. Univariable and multivariable logistic regression analyses were performed to identify factors associated with AKI.

Results: Of 650 patients assessed, 604 were included in the cohort, and 592 were included in the final propensity score–matched cohort, with post matching absolute standardized mean differences <0.05 for all matched covariates. The overall incidence of AKI was 15.2% (92/604), including stage 1 (n=32), stage 2 (n=23), and stage 3 (n=37). Renal replacement therapy was required in 24 patients (CRRT, n=4; acute hemodialysis, n=2; acute peritoneal dialysis, n=18), most commonly due to fluid overload (n=22). Renal recovery occurred in 56.5% (52/92) of AKI cases. Dextran-40 administration was not significantly associated with AKI in either univariable or multivariable analyses. DHF grade IV, refractory shock, and male sex were independently associated with AKI, with refractory shock showing the strongest association. Among dextran-40 recipients, administration > 60 minutes after initiation of fluid resuscitation was independently associated with increased odds of AKI in both the primary and severity-adjusted models, a finding that persisted in the subgroup of patients receiving dextran-40 specifically for shock. A higher cumulative dextran-40 dose was associated with increased odds of AKI in the primary model, but this association was attenuated after adjustment for disease severity.

Conclusion: Dextran-40 administration was not independently associated with AKI; instead, delayed administration (>60 minutes after fluid resuscitation initiation) and disease severity, particularly refractory shock and DHF grade IV, were the key potentially modifiable and non-modifiable predictors of AKI risk, respectively. These findings support continued use of dextran-40 as colloid therapy in pediatric DSS while emphasizing the importance of timely administration to minimize AKI risk.